Literature DB >> 2902492

Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

P Saikku1, M Leinonen, K Mattila, M R Ekman, M S Nieminen, P H Mäkelä, J K Huttunen, V Valtonen.   

Abstract

Paired sera from 40 male patients with acute myocardial infarction (AMI), 30 male patients with chronic coronary heart disease (CCHD), and 41 controls, matched for sex, age, time, and locality were investigated for antibodies to a novel type of Chlamydia sp, TWAR, and to chlamydial lipopolysaccharide (LPS) group antigen. 27 patients with AMI (68%), and 15 (50%) patients with CCHD had raised IgG (greater than or equal to 128) and/or IgA (greater than or equal to 32) titres in the microimmunofluorescence test with chlamydia TWAR. Both frequencies were significantly higher than in the controls (7, 17%). 26 (68%) of 38 patients with AMI also showed a significant seroconversion in enzyme immunoassay with LPS antigen; this response was absent in all patients with CCHD and all but 1 of the controls. Chronic chlamydial infection could be a factor in the pathogenesis of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902492     DOI: 10.1016/s0140-6736(88)90741-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  266 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis.

Authors:  J D Rutherford
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods.

Authors:  A Meijer; P J Roholl; S K Gielis-Proper; Y F Meulenberg; J M Ossewaarde
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

3.  Optimizing culture of Chlamydia pneumoniae by using multiple centrifugations.

Authors:  J M Pruckler; N Masse; V A Stevens; L Gang; Y Yang; E R Zell; S F Dowell; B S Fields
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

4.  The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae.

Authors:  Y K Wong; J M Sueur; C H Fall; J Orfila; M E Ward
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

Review 5.  Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

6.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; L Ballam; J Morris; B K Butland; P M Sweetnam; P C Elwood
Journal:  BMJ       Date:  1999-04-17

7.  Cell-mediated immune response during primary Chlamydia pneumoniae infection.

Authors:  S Halme; J Latvala; R Karttunen; I Palatsi; P Saikku; H M Surcel
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

8.  Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells.

Authors:  J B Mahony; S Chong; B K Coombes; M Smieja; A Petrich
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

9.  Characterization of Chlamydia pneumoniae persistence in HEp-2 cells treated with gamma interferon.

Authors:  L G Pantoja; R D Miller; J A Ramirez; R E Molestina; J T Summersgill
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 10.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.